FILTERED RESULTS
FILTERS
Ads Top
DARK MODE
CHART
    Filters
      Symbols
      Sentiment
      Impact
      Search
      FILTERED RESULTS

        

      Upgrade your plan
      ·

      vrtx

      ·

      FDA Expands Use of Vertex Pharmaceuticals' Cystic Fibrosis Drugs

      Vertex Pharmaceuticals has gained renewed attention following the U.S. Food and Drug Administration's decision to expand the use of its cystic fibrosis treatments, ALYFTREK and TRIKAFTA. This expansion significantly increases the number of patients eligible for these therapies in the United States.

      The FDA's label changes come at a time when Vertex's stock has experienced a decline, with a 3.68% drop over the past month and a total shareholder return of 7.96% over the past year. Despite these recent challenges, the company has seen more favorable returns over the past three to five years, indicating potential resilience in its long-term performance.

      © 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

      Source: KLEA News

      .

      Terra Founder Do Kwon Sentenced to 15 Years in Prison for Fraud